This week, Epigenomics said it had validated two prognostic markers for a breast-cancer diagnostic that could compete with Genomic Health's Oncotype Dx, but was abandoned by former partner Roche Diagnostics, the company said this week.

The study examined the use of Epigenomics' main DNA methylation biomarker, PITX2, as well as a secondary marker, to predict breast cancer recurrence in 395 patients with estrogen receptor-positive, node-positive cancer who had been treated with the chemotherapeutic anthracycline as adjuvant therapy.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Jay Shendure and his colleagues have developed a new method to more comprehensively identify human cell types, the NY Times reports.

Researchers in the UK and Japan have shown that infertility in mice with three sex chromosomes can be overcome, according to the Guardian.

China is embracing preimplantation genetic diagnosis, Nature News reports. 

In PLOS this week: host genetic factors associated with cervical neoplasia progression, population patterns for an ancient flowering rainforest plant, and more.